Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Goodman

Showing results (831-840 of 1,119) with videos related to

Pageof 112
Sort By:
American Heart Journal Plus : Cardiology Research and Practice|September 15, 2025
Real-world effectiveness of early revascularization in stable coronary artery disease with moderate or severe ischemiaFerdinand Jr Gerodias, Robert M Iwanochko, Peter C Austin, et al.
Open Heart|December 16, 2021
Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarctionAnthony P Carnicelli, Ruth Owen, Stuart J Pocock, et al.
CJC Open|September 2, 2025
Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEARTWade Thompson, Brendan Wong, Atul Sivaswamy, et al.
The Canadian Journal of Cardiology|November 10, 2009
Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratificationS Jedrzkiewicz, S G Goodman, R T Yan, et al.
Clinical Cardiology|December 17, 2017
Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) studyDirk Westermann, Shaun G Goodman, José C Nicolau, et al.
Circulation|September 2, 2008
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38Stephen D Wiviott, Eugene Braunwald, Dominick J Angiolillo, et al.
Circulation|March 7, 1998
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic InvestigatorsS G Goodman, A Langer, A M Ross, et al.
Kidney International|August 18, 2005
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HClKevin J Martin, Harald Jüppner, Donald J Sherrard, et al.
The American Journal of Cardiology|May 30, 1998
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary ArteriesJ Hochrein, F Sun, K S Pieper, et al.
BMJ (Clinical Research Ed.)|October 13, 2006
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)Keith A A Fox, Omar H Dabbous, Robert J Goldberg, et al.
Pageof 112

Showing results (831-840 of 1,119) with videos related to

Sort By:
Pageof 112
American Heart Journal Plus : Cardiology Research and Practice|September 15, 2025
Real-world effectiveness of early revascularization in stable coronary artery disease with moderate or severe ischemiaFerdinand Jr Gerodias, Robert M Iwanochko, Peter C Austin, et al.
Open Heart|December 16, 2021
Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarctionAnthony P Carnicelli, Ruth Owen, Stuart J Pocock, et al.
CJC Open|September 2, 2025
Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEARTWade Thompson, Brendan Wong, Atul Sivaswamy, et al.
The Canadian Journal of Cardiology|November 10, 2009
Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratificationS Jedrzkiewicz, S G Goodman, R T Yan, et al.
Clinical Cardiology|December 17, 2017
Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) studyDirk Westermann, Shaun G Goodman, José C Nicolau, et al.
Circulation|September 2, 2008
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38Stephen D Wiviott, Eugene Braunwald, Dominick J Angiolillo, et al.
Circulation|March 7, 1998
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic InvestigatorsS G Goodman, A Langer, A M Ross, et al.
Kidney International|August 18, 2005
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HClKevin J Martin, Harald Jüppner, Donald J Sherrard, et al.
The American Journal of Cardiology|May 30, 1998
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary ArteriesJ Hochrein, F Sun, K S Pieper, et al.
BMJ (Clinical Research Ed.)|October 13, 2006
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)Keith A A Fox, Omar H Dabbous, Robert J Goldberg, et al.
Pageof 112